Stem Cell Clinic

Why Cynata is hopeful its COVID treatment trial will succeed where others have failed – Business News Australia

Cynata Therapeutics (ASX: CYP), founded by two clever stem cell researchers and one wise Australian techpreneur, is in the process of developing a treatment for COVID-19.

Using its in-house stem cell technology Cymerus, the ASX-listed biotech hopes to treat one of the deadliest complications of COVID-19 -acute respiratory distress syndrome (ARDS).

In doing so Cynata would achieve what competitor Mesoblast (ASX: MSB) couldn't with FDA approval.

By deploying an industrialised approach to stem cell therapeutics, Cynata CEO Ross Macdonald (pictured) is confident the clinical trial process won't leave the company hamstrung.

In 1981 scientists discovered a way to derive embryonic stem cells from early mouse embryos.

The discovery thrilled scientists, and eventually led to the development of a method to do the same in lab-grown human embryos by 1998.

While there have been plenty of discussions surrounding the ethics of using of embryonic stem cells, these major scientific movements have pushed researchers to discover new and inventive ways of treating a whole raft of diseases and infections.

One such researcher, Dr Ian Dixon, saw potential for the use of mesenschymal stem cells (MSCs) - a type of stem cell that can differentiate into a variety of cell types enabling the treatment of many diseases and infections.

However there was still an obstacle to overcome: how do you mass produce enough cells needed to commercialise a treatment?

Luckily, two researchers at the University of Wisconson, Professor Igor Slukvin and Dr Maksym Vodyanik, had invented a biotechnological breakthrough called Cymerus.

The technology was able to do exactly what Dixon needed: the consistent manufacture of MSCs on an ultra-large scale; basically what Henry Ford did to the industrialisation of the auto industry, but for stem cells.

So in 2003 Dixon partnered with the two researchers to start Cynata - now an ASX-listed biotechnology company trialing a number of different treatments for a wide variety of ailments.

Most recently, Cynata's focus has been on developing a treatment for a complication of COVID-19 called acute respiratory distress syndrome (ARDS).

The complication ravages COVID-19 infected patients, destroying their organs through what is known as a cytokine storm. The complication is estimated to kill up to half of COVID-19 patients that suffer from it.

Melbourne-based Cynata is currently in the very early stages of its investigation into whether its MSCs will be able to treat the coronavirus complication overwhelming hospitals globally.

If this all sounds familiar, you might be thinking of another ASX-listed biotech called Mesoblast (ASX: MSB).

In March last year Mesoblast, also based in Melbourne, saw its shares surge after announcing plans to evaluate its stem cell treatment solutions on COVID-19 patients.

The group commenced the arduous clinical trial process to see if its remestemcel-L therapy could treat ARDS by using bone marrow aspirate from healthy donors - a similar approach the company had already taken to treat a condition many suffer from after receiving bone marrow transplants.

Mesoblast was riding high on the ASX following positive announcements surrounding the clinical traila process, especially back in April 2020 when a trial at New York City's Mt Sinai hospital found its remestemcel-L therpay achieved "remarkable" results.

Serious attention gathered around Mesoblast, with the company even securing $138 in funds from investors to continue its important research.

The company went so far as to sign a commercialisation deal for the COVID-19 treatment with Novartis, and the US Food and Drugs Administration (FDA) fast tracked the approvals process for the potential game-changing treatment.

However, in December 2020, Mesoblast hit a stumbling block.

Mesoblast's COVID-19 treatment flunked the test - its remestemcel-L therapy failed to show a lower mortality rate for patients in the prescribed 30-day timeframe of treatment.

At that point Cynata had commenced research into its own ARDS treatment. But did Mesoblast's failure unnerve Cynata CEO Ross Macdonald? Not a chance.

"I'm more confident that our trial will be successful where theirs was a failure," Macdonald said.

"If you use a process like we have developed - we don't rely on multiple different [stem cell] donations. You start with exactly the same material every time."

To explain, Macdonald used the analogy of a local caf; you normally expect a coffee from one caf to taste more or less exactly the same every time you go there - the same beans are used every time.

Whereas Macdonald said Mesoblast's process is like going to the same caf every day, but each visit they use different beans from a different supplier which leads to inconsistency in taste and flavour.

Cynata's approach with its MSCs is in line with the first example - what you get the first time from them will be replicated in each and every dose of the drug - while MSB's is like the latter.

"Yes, you still got the coffee, but the experience of the taste is totally different than it was yesterday," he said.

"The FDA said to Mesoblast, well you've got a manufacturing problem that is reliant upon multiple donors prepared to donate bone marrow and that is flawed.

"So with that in mind it's perhaps not surprising that they had a pretty disappointing result in the clinical trials."

Additionally, Macdonald said the initial investor reactions to MSB's early COVID-19 trail results were overblown.

"The initial data from their trial that got everybody excited was, in my view, quite flawed, because they said "look at how many patients are dying in intensive care units with COVID compared the patients that we treated," he said.

"But the reality of the situation was quite different. The control group at that time - the death rate was way, way higher than you would typically see for ARDS, whether its COVID or anything else. And it was simply because of the chaos that existed in intensive care units in New York in the first wave.

"So we think that the initial enthusiasm was perhaps a little misguided."

When asked why Mesoblast is receiving so much attention compared to Cynata, especially considering the above, Macdonald said it was simply because MSB is bigger and has been around for longer. For context, MSB has a market capitalisation of $1.46 billion, whereas Cynata's is just $94.56 million.

"I'd love to know why there is less attention, and how we can get our market cap above a billion dollars," joked Macdonald.

"I think the answer though is that they've been around for a lot longer than we have, they have spent a hell of a lot more money than we've spent - their monthly spend is more than we've spent for pretty much our entire existence.

"But I think the fundamental reason why is that data drives value in biotech, so the more clinical data you generate that shows your product works, the more attention you attract from investors."

That's not to say Cynata is being totally ignored in favour of the larger Mesoblast.

The company secured a $15 million placement led by $10 million from healthcare investor BioScience Managers in December.

The funds will be used to expand Cynata's clinical development pipeline and scale their operations in Australia.

As such, the company is preparing to expand its clinical development pipeline to include idiopathic pulmonary fibrosis, renal transplantation, and diabetic foot ulcers.

"So we're starting to garner that attention now that says two things - one, cell therapies are definitely a medical revolution and two, Cynata is part of that new generation of companies," Macdonald said.

As for the company's pipeline, in addition to the COVID treatment trials, Cynata is planning on launching three new clinical candidates that will get under way this year.

There's also Cynata's osteoarthritis trial, which Macdonald describes as significant for the biotech company; with 2 million patients in Australia and 30 million in the United States the company is hoping to tap into an $11 billion plus addressable market.

"It will ultimately show whether MSCs are useful in that particularly devastating condition," he said.

"It doesn't just affect people who want to go and play golf or tennis, it affects, particularly manual labourers who can no longer work.

"So the cost to the economy of osteoarthritis is quite significant, which is of course one of the reasons why the Australian Government is funding this trial."

Never miss a news update, subscribe here. Follow us on Facebook, LinkedIn, Instagram and Twitter.

Business News Australia

View post:
Why Cynata is hopeful its COVID treatment trial will succeed where others have failed - Business News Australia

Missouri State Representative Indicted Over Alleged Stem Cell Therapy Scam – IFLScience

Tricia Derges, a member of the Missouri House of Representatives and doctor, has been indicted by a grand jury for among other things allegedly injecting people with amniotic fluid and telling them mesenchymal stem cells made it a miracle cure. Derges has pled not guilty, and IFLScience cannot assess the accuracy of the charges. However, the case brings attention to growing use of unproven and dangerous stem cell treatments.

The case against Derges is being taken by Tim Garrison, the U.S. Attorney for Missouri's Western District. Garrison alleges Derges acquired stem cell-free amniotic fluid and told patients it contained stem cells that would cure a variety of conditions, charging them four times what the fluid cost her to inject them with it. Garrison charged Derges with false statements over the use of the fluid, as well as illegal distribution of controlled substances and wire fraud in relation to other activities at the clinics she runs.

Among long posts on her Facebook page professing her innocence, Derges posted a picture of David and Goliath, writing, I actually thought that I was making a difference. What I didnt account for was how much satan would fight back.

Whatever the truth of the allegations in Derges' specific case, by charging astate representative, Garrison has highlighted what is definitely a growing problem: deceptive use of stem cell therapies.

Multipotent stem cells have the remarkable capacity to convert into the cells that make up many bodily tissues. The hematopoietic stem cells have been used for decades to treat leukemia with well-proven results. Hundreds of other applications are either under investigation in the laboratory, or currently in clinical trials, but a much smaller number have been approved by America's FDA and equivalent bodies worldwide.

Understandably, many people don't feel able to wait, making them vulnerable to quack doctors for whom stem cells are the 21st Century snake oil. Unlike embryonic stem cells, which often originate from abortions, amniotic stem cells are seen as an alternative acceptable to pro-life individuals. However, having been discovered more recently, research into them is less advanced, making any therapeutic value speculative.

Dirges' vocal opposition to abortionpresumably made amniotic cells attractive to her for this reason, but Garrison alleges the fluid Derges was using didn't even contain stem cells. Moreover, he claims the University of Utah where Derges bought the fluid told her that, so she would have known it couldn't possibly have been effective.

Derges gained a medical degree from the Caribbean Medical University in Curaao and ran a series of low-cost medical clinics, where volunteers saw patients and recommended to her what medication to prescribe. Although licensed as an assistant physician, Derges was not accepted into a post-graduate residency program and was not licensed as a physician. She fought to change licensing rules, and ran for Missouri state District 140, narrowly winning the Republican primary before being unopposed last November. Since being elected, Derges has made changing the law on physician licensing her first priority.

In a statement, Garrison allegedDerges used the fluid on patients with everything from Lyme disease to erectile dysfunction and kidney disease, despite the improbability a single fluid would cure such different ills. Although Derges' clinics are famous for charging just $5 for an ordinary visit, the costs of this treatment averaged $40,000 per patient.

The program came to Garrison's attention after she appeared on television claiming the same amniotic fluid should be used to treat COVID-19 and making similar claims on Facebook.

H/T Springfield News Leader

Read more here:
Missouri State Representative Indicted Over Alleged Stem Cell Therapy Scam - IFLScience

Global Human Embryonic Stem Cells Market increasing demand with Industry Professionalist |know the Brand Players forecast 2027 Jumbo News – Jumbo…

Global Human Embryonic Stem Cells Market 2021IndustrialAnalysis, Regional Survey, and Forecast Report: Supply, Demand, Suppliers, Porters Five Forces Analysis, Segment-wise Trends, Statistical Survey, Pricing Analysis, Geographical Exploration, Revenues, Historical Data, and Projections to 2027

This research study evaluates the global Human Embryonic Stem Cellsmarket status, growth rate, player market shares, player positioning, projection trends, competition landscape, market drivers, challenges and opportunities, pricing analysis, deployment channels, and distributors.Syndicate Market Research AnalysesResearch Methodology overview consists ofSecondary Research,Primary Research,Company Share Analysis,Model ( including Demographic data, Macroeconomic indicators, andIndustry indicators i.e. Expenditure, infrastructure, sector growth, and facilities, etc),Research Limitations and Revenue Based Modeling.The establishment of the Human Embryonic Stem Cells showcase is additionally referenced in the report that can permit the customers in applying essential strategies to increase the upper hand. Such a sweeping and through and through research investigation gives the fundamental development with key proposals and impartial quantifiable examination. This can be utilized to upgrade the present position and structure future expansions in a particular zone in the Human Embryonic Stem Cells showcase. The report likewise gauges inclines in the market alongside mechanical headways in the business.It also has an In-depth analysis of the industrys competitive landscape, restraints, detailed information about different drivers, and global opportunities. Key competitors included in Global Human Embryonic Stem Cells Market areESI BIO, Thermo Fisher, BioTime, MilliporeSigma, BD Biosciences, Astellas Institute of Regenerative Medicine, Asterias Biotherapeutics, Cell Cure Neurosciences, PerkinElmer, Takara Bio, Cellular Dynamics International, Reliance Life Sciences, Research & Diagnostics Systems, SABiosciences, STEMCELL Technologies, Stemina Biomarker Discovery, Takara Bio, TATAA Biocenter, UK Stem Cell Bank, ViaCyte, Vitrolife

Our Research SpecialistAnalysesResearch Methodology overview includingPrimary Research, Secondary Research, Company Share Analysis,Model ( including Demographic data, Macro-economic indicators, andIndustry indicators: Expenditure, infrastructure, sector growth, and facilities ),Research Limitations and Revenue Based Modeling. Company share analysis is used to derive the size of the global market. As well as a study of revenues of companies for the last three to five years also provides the base for forecasting the market size (2021- 2027) and its growth rate.Porters Five Forces Analysis, impact analysis of covid-19 and SWOT Analysisare also mentioned tounderstand the factors impacting consumer and supplier behaviour.

FREE | Request Sample is Available For Human Embryonic Stem Cells Industry Report @https://www.syndicatemarketresearch.com/sample/human-embryonic-stem-cells-market

Dont miss out on business opportunities in Human Embryonic Stem Cells Market. Speak to our analyst and gain crucial industry insights that will help your business growth while filling Free PDF Sample Reports

(The sample of this report is readily available on request).

This Free report sample includes :

The point of this exploration report is to characterize, break down, portion, and estimate the size of the Human Embryonic Stem Cells showcase based on types, applications, end-clients, key districts, and key players. This report gives the worldwide market size of Human Embryonic Stem Cells in key topographies viz.Europe, North America, Asia Pacific, Central, and South America Middle East and Africa, with the prime spotlight on significant economies including Canada, U.S, Mexico, UK, Germany, Spain, France, Russia, Italy, India, China, South Korea, Japan, Southeast Asia, Indonesia, Australia, Argentina, Brazil, South Africa, GCC nations, Turkey and Egypt among other remarkable nations in rest of the world.The report centers around the offers of Human Embryonic Stem Cells in the previously mentioned districts/ nations. This exploration report arranges the worldwide Human Embryonic Stem Cells showcase by top brands/players/sellers, type, applications, end-users, regions, and Countries

Key Highlights of the TOC provided by Syndicate Market Research:

Major Product Type of Human Embryonic Stem Cells Covered in Market Research report:Totipotent Stem Cells, Pluripotent Stem Cells, Unipotent Stem Cells

Application Segments Covered in Market Research Report:Research, Clinical Trials

Global Human Embryonic Stem Cells Industry Market: By Region

North America

Europe

Asia Pacific

Latin America

The Middle East and Africa

Table of Content include Human Embryonic Stem Cells Market Worldwide are:

1 Study Coverage 1.1 Human Embryonic Stem Cells Product 1.2 Key Market Segments in This Study 1.3 Key Manufacturers Covered 1.4 Market by Type 1.4.1 GlobalMarket Size Growth Rate by Type (Totipotent Stem Cells, Pluripotent Stem Cells, Unipotent Stem Cells) 1.5 Market by Application 1.5.1 Global Market Size Growth Rate by Application (Research, Clinical Trials) 1.6 Study Objectives 1.7 Years Considered

2 Executive Summary 2.1 Global Human Embryonic Stem Cells Market Size 2.1.1 Global Human Embryonic Stem Cells Revenue 2013-2025 2.1.2 Global Human Embryonic Stem Cells Production 2013-2025 2.2 Human Embryonic Stem Cells Growth Rate (CAGR) 2021-2027 2.3 Analysis of Competitive Landscape 2.3.1 Manufacturers Market Concentration Ratio (CR5 and HHI) 2.3.2 Key Manufacturers 2.3.2.1 Manufacturing Base Distribution, Headquarters 2.3.2.2 Manufacturers Product Offered 2.3.2.3 Date of Manufacturers Enter into Market 2.4 Key Trends for Markets & Products

3 Human Embryonic Stem Cells Market Size by Manufacturers 3.1 Production by Manufacturers 3.1.1Production by Manufacturers 3.1.2 Production Market Share by Manufacturers 3.2 Revenue by Manufacturers 3.2.1 Revenue by Manufacturers (2013-2018) 3.2.2 Revenue Share by Manufacturers (2013-2018) 3.3 Price by Manufacturers 3.4 Mergers & Acquisitions, Expansion Plans

4 Human Embryonic Stem Cells Production by Regions 4.1 Global Production by Regions 4.1.1 Global Production Market Share by Regions 4.1.2 Global Revenue Market Share by Regions 4.2 United States 4.2.1 United States Production 4.2.2 United States Revenue 4.2.3 Key Players in United States 4.2.4 United States Import & Export 4.3 Europe 4.3.1 Europe Production 4.3.2 Europe Revenue 4.3.3 Key Players in Europe 4.3.4 Europe Import & Export 4.4 China 4.4.1 China Production 4.4.2 China Revenue 4.4.3 Key Players in China 4.4.4 China Import & Export 4.5 Japan 4.5.1 Japan Production 4.5.2 Japan Revenue 4.5.3 Key Players in Japan 4.5.4 Japan Import & Export 4.6 Other Regions 4.6.1 South Korea 4.6.2 India 4.6.3 Southeast Asia

5 Human Embryonic Stem Cells Consumption by Regions 5.1 Global Human Embryonic Stem Cells Consumption by Regions 5.1.1 Global Human Embryonic Stem Cells Consumption by Regions 5.1.2 Global Human Embryonic Stem Cells Consumption Market Share by Regions 5.2 North America 5.2.1 North America Human Embryonic Stem Cells Consumption by Application 5.2.2 North America Human Embryonic Stem Cells Consumption by Countries 5.2.3 United States 5.2.4 Canada 5.2.5 Mexico 5.3 Europe 5.3.1 Europe Human Embryonic Stem Cells Consumption by Application 5.3.2 Europe Human Embryonic Stem Cells Consumption by Countries 5.3.3 Germany 5.3.4 France 5.3.5 UK 5.3.6 Italy 5.3.7 Russia 5.4 Asia Pacific 5.4.1 Asia Pacific Human Embryonic Stem Cells Consumption by Application 5.4.2 Asia Pacific Human Embryonic Stem Cells Consumption by Countries 5.4.3 China 5.4.4 Japan 5.4.5 South Korea 5.4.6 India 5.4.7 Australia 5.4.8 Indonesia 5.4.9 Thailand 5.4.10 Malaysia 5.4.11 Philippines 5.4.12 Vietnam 5.5 Central & South America 5.5.1 Central & South America Human Embryonic Stem Cells Consumption by Application 5.5.2 Central & South America Human Embryonic Stem Cells Consumption by Country 5.5.3 Brazil 5.6 Middle East and Africa 5.6.1 Middle East and Africa Human Embryonic Stem Cells Consumption by Application 5.6.2 Middle East and Africa Human Embryonic Stem Cells Consumption by Countries 5.6.3 GCC Countries 5.6.4 Egypt 5.6.5 South Africa

6 Market Size by Type 6.1 Global Production by Type 6.2 Global Revenue by Type 6.3 Price by Type

7 Market Size by Application 7.1 Overview 7.2 Global Breakdown Dada by Application 7.2.1 Global Consumption by Application 7.2.2 Global Consumption Market Share by Application (2021-2027)

8 Manufacturers Profiles Overall Companies available in Human Embryonic Stem Cells Market 8.1.1 Company Details 8.1.2 Company Overview 8.1.3 Company Human Embryonic Stem Cells Production Revenue and Gross Margin (2014-2020) 8.1.4 Human Embryonic Stem Cells Product Description 8.1.5 Recent Development and others

9 Production Forecasts 9.1 Human Embryonic Stem Cells Production and Revenue Forecast 9.1.1 Global Human Embryonic Stem Cells Production Forecast 2021-2027 9.1.2 Global Human Embryonic Stem Cells Revenue Forecast 2021-2027 9.2 Human Embryonic Stem Cells Production and Revenue Forecast by Regions 9.2.1 Global Human Embryonic Stem Cells Revenue Forecast by Regions 9.2.2 Global Human Embryonic Stem Cells Production Forecast by Regions 9.3 Human Embryonic Stem Cells Key Producers Forecast 9.3.1 United States 9.3.2 Europe 9.3.3 China 9.3.4 Japan 9.4 Forecast by Type 9.4.1 Global Human Embryonic Stem Cells Production Forecast by Type 9.4.2 Global Human Embryonic Stem Cells Revenue Forecast by Type

10 Consumption Forecast 10.1 Human Embryonic Stem Cells Consumption Forecast by Application 10.2 Human Embryonic Stem Cells Consumption Forecast by Regions 10.3 North America Market Consumption Forecast 10.3.1 North America Human Embryonic Stem Cells Consumption Forecast by Regions 2021-2027 10.3.2 United States 10.3.3 Canada 10.3.4 Mexico 10.4 Europe Market Consumption Forecast 10.4.1 Europe Human Embryonic Stem Cells Consumption Forecast by Regions 2021-2027 10.4.2 Germany 10.4.3 France 10.4.4 UK 10.4.5 Italy 10.4.6 Russia 10.5 Asia Pacific Market Consumption Forecast 10.5.1 Asia Pacific Human Embryonic Stem Cells Consumption Forecast by Regions 2021-2027 10.5.2 China 10.5.3 Japan 10.5.4 South Korea 10.5.5 India 10.5.6 Australia 10.5.7 Indonesia 10.5.8 Thailand 10.5.9 Malaysia 10.5.10 Philippines 10.5.11 Vietnam 10.6 Central & South America Market Consumption Forecast 10.6.1 Central & South America Human Embryonic Stem Cells Consumption Forecast by Regions2021-2027 10.6.2 Brazil 10.7 Middle East and Africa Market Consumption Forecast 10.7.1 Middle East and Africa Human Embryonic Stem Cells Consumption Forecast by Regions 2021-2027 10.7.2 GCC Countries 10.7.3 Egypt 10.7.4 South Africa

11 Value Chain and Sales Channels Analysis 11.1 Value Chain Analysis 11.2 Sales Channels Analysis 11.2.1 Human Embryonic Stem Cells Sales Channels 11.2.2Distributors 11.3Customers

12 Market Opportunities & Challenges, Risks and Influences Factors Analysis 12.1 Market Opportunities and Drivers 12.2 Market Challenges 12.3 Market Risks/Restraints 12.4 Key World Economic Indicators

13 Key Findings in the Global Human Embryonic Stem Cells Study

14 Appendix 14.1 Research Methodology 14.1.1 Methodology/Research Approach 14.1.1.1 Research Programs/Design 14.1.1.2 Market Size Estimation 14.1.1.3 Market Breakdown and Data Triangulation 14.1.2 Data Source 14.1.2.1 Secondary Sources 14.1.2.2 Primary Sources 14.2 Author Details 14.3 Disclaimer

If you want Special Requirement or any other report Requirement, Ask our Industry Experts

Read Our Other Exclusive Blogs:

https://marktwachstum24.blogspot.com/2021/01/global-online-display-advertising.html

https://in.pinterest.com/pin/335307134762736777

About Syndicate Market Research:

At Syndicate Market Research, we provide reports about a range of industries such as healthcare & pharma, automotive, IT, insurance, security, packaging, electronics & semiconductors, medical devices, food & beverage, software & services, manufacturing & construction, defence aerospace, agriculture, consumer goods & retailing, and so on. Every aspect of the market is covered in the report along with its regional data. Syndicate Market Research committed to the requirements of our clients, offering tailored solutions best suitable for strategy development and execution to get substantial results. Above this, we will be available for our clients 247.

Read this article:
Global Human Embryonic Stem Cells Market increasing demand with Industry Professionalist |know the Brand Players forecast 2027 Jumbo News - Jumbo...

Push on to Allow Expanded Human-Embryo Research – National Review

(gorodenkoff/Getty Images)

Back when embryonic-stem-cell and other types of experimentation on early embryos commenced, the scientists promised they would always limit their activities to embryos in Petri dishes to the maximum of 14 days in development. Just a collection of undifferentiated cells, they sophistically maintained. Well stop when the nervous system begins to develop.

It was all a ruse. The 14 day rule, as it came to be known, only prevented that which could not be done. You see, the state of the science was such that embryos could not be maintained for longer. But it assuaged the peasants. Besides, the scientists knew that the boundary wasnt intended to be permanent. It was just a way station until embryos could be maintained outside a womans body for more than two weeks.

That time is now arriving, and so, of course, the push is now on to expand the limit to 28 days.

How is that justified, based on past assurances? Well, first deploy relativism.

Scientifically, an embryo is an embryo, wherever it might be located. But well pretend that what really matters regarding moral value is geography. From The Time has Come to Extend the 14-Day Limit:

Elsejin Kingma considers the idea that the location of an embryowhether it is in a pregnant woman or in a petri-dishmay affect its moral status and/or value. She argues that it is not just the stage of the embryo that is relevant to its moral status or value, but whether it is, or will be, in an environment that promotes its further development. She concludes that this means there is (further) good reason for a moral distinction between research embryos and reproductive implanted embryos.

Given that almost all if not all of these bioethicists believe in abortion on demand, this is a load of hooey. Yes, that is the logic, and the paper goes there:

Notwithstanding the importance of the scientific basis for human embryo research, there are ethical and philosophical reasons why this rule is now ready for amendment.

In the UK, in line with the Abortion Act 1967, an abortion is legally permitted up to the 24th week of pregnancy. Conventionally, a human embryo is termed a fetus from 9 weeks after fertilisation. It is legal to abort an embryo or fetus substantially older than 14 days, and, with appropriate consent, to do research on its tissues, yet it is illegal to experiment on an embryo beyond 14 days that was never to be implanted.

Why stop at 28 days? What are the limiting principles? What is the permanent line with regard to unborn life beyond which science will never be allowed to go regardless of the potential knowledge to be attained especially in the U.S., where some states have removed gestational limits on abortion and that is the goal of the national Democratic Party and Biden administration?I cant see any.

How is this excused? Princetons Peter Singer the New York Times favorite moral philosopher and other bioethicists claim that human life, per se, is morally irrelevant. What matters are capacities such as self-awareness that earn that human being the label of person.

Embryos are not conscious. Neither are fetuses. They are, hence, human non-persons. So why not permit experimentation and body-part harvesting through the ninth month since, in essence, unborn life are mere things? Indeed, before that time arrives, why not pay women to gestate longer before obtaining an abortion so we could get the parts an odious idea already proposed in the bioethics literature.

This isnt just philosophical musing. We may soon have the ability to maintain fetuses in artificial wombs. Once that happens, what is to prevent scientists from creating embryos, implanting them in artificial wombs and treating fetuses as a mere natural resource to be exploited and harvested?

Live fetal experimentation was conducted in the late 60s, after all, and was only stopped (pre-Roe) because people still believed in the sanctity of human life. That great moral principle no longer holds sway over great swaths of society. The important thing now is preventing suffering by almost any means necessary.

I could go on and on, and probably will. But the bottom line for this post is this: When scientists and bioethicists promise to draw ethical lines about experimenting on unborn life, they dont really mean it. Its all a big con. They will only agree to forbid that which they cannot yet do. And once they can go there, the lines will be redrawn to permit them to do whatever they want.

And then they wonder, Where is the trust?

Read this article:
Push on to Allow Expanded Human-Embryo Research - National Review

Stem Cell Therapy Market Size, Top Key Players, Applications, Business Statistics, Trends and Forecast 2021-2027 The Bisouv Network – The Bisouv…

Allosource

The global informative report begins with a brief introduction of Stem Cell Therapy market and market overview, classification, application, technologies, products or services, and key players operating across the globe. The global informative report elaborates on the global market scope, market scope at the present, and prediction of demand from global clients in the future. The global market research report has been presented in a clear and professional manner for easy and better understanding to readers. The driving forces, limitations, and global opportunities are listed for the Stem Cell Therapy market to get the gist of different dynamics of the global market. It has been compiled through proven research techniques such as primary research and secondary research.

Request a Discount on the report @ https://reportsglobe.com/ask-for-discount/?rid=33553

Market Segments and Sub-segments Covered in the Report are as per below:

1.Stem Cell Therapy Market, By Cell Source:

Adipose Tissue-Derived Mesenchymal Stem Cells Bone Marrow-Derived Mesenchymal Stem Cells Cord Blood/Embryonic Stem Cells Other Cell Sources

2.Stem Cell Therapy Market, By Therapeutic Application:

Musculoskeletal Disorders Wounds and Injuries Cardiovascular Diseases Surgeries Gastrointestinal Diseases Other Applications

3.Stem Cell Therapy Market, By Type:

Allogeneic Stem Cell Therapy Market, By Application Musculoskeletal Disorders Wounds and Injuries Surgeries Acute Graft-Versus-Host Disease (AGVHD) Other Applications Autologous Stem Cell Therapy Market, By Application Cardiovascular Diseases Wounds and Injuries Gastrointestinal Diseases Other Applications

Geographical scenario:

The geographical analysis of the Stem Cell Therapy market has been done by examining different global regions such as North America, Latin America, Middle East, Asia-Pacific, and Africa on the basis of different parameters. The primary target for the Stem Cell Therapy market are the Stem Cell Therapy countries. The Stem Cell Therapy market has broadly compiled through extensive research and analysis techniques such as qualitative and quantitative analysis. Furthermore, it offers a blend of SWOT and Porters five techniques to analyze the data of the global market. Moreover, this report offers a complete analysis of different business perspectives such as the ups and downs of the global market shares. To expand the market at the global level, it makes use of different techniques and sales methodologies for achieving the outcomes of the businesses.

Collectively, this research repository encapsulates data of Stem Cell Therapy market to offer strategic decision-making abilities to various investors, business owners, decision-makers as well as policymakers.

The Stem Cell Therapy Market is divided into the following regions:

North America (USA, Canada) Latin America (Chile, Brazil, Argentina, rest of Latin America) Europe (UK, Italy, Germany, France, rest of the EU) Asia Pacific (India, Japan, China, South Korea, Australia, rest of APAC) Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa, rest of MEA)

View market snapshot before purchasing @ https://reportsglobe.com/product/global-stem-cell-therapy-market/

Following major key questions are addressed through this global research report:

1. What will be the Stem Cell Therapy market size over the forecast period? 2. What are the demanding regions for making significant growth in the upcoming future? 3. What are the challenges in front of the Stem Cell Therapy market? 4. Who are the key vendors in Stem Cell Therapy market? 5. What are the effective sales patterns and methodologies for boosting the performance of the Stem Cell Therapy market? 6. What are the different ways to find out potential customers as well as global clients? 7. Which factors are hampering the Stem Cell Therapy market? 8. What are the outcomes of SWOT and porters five techniques? 9. What are the demanding trends of the Stem Cell Therapy market?

Key strategic developments in the Stem Cell Therapy market:

This global study also includes the key strategic developments of the Stem Cell Therapy market including the new product launchings, partnerships and collaboration among the key players functioning at the global level.

Request customization of the report @ https://reportsglobe.com/need-customization/?rid=33553

Key target audience for Stem Cell Therapy report:

The report is insightful documentation and provides significant insights to customers, business owners, decision-makers, providers, distributors, suppliers, policymakers, manufacturers, investors, and individuals who have a keen interest in the Stem Cell Therapy market.

How Reports Globe is different than other Market Research Providers:

The inception of Reports Globe has been backed by providing clients with a holistic view of market conditions and future possibilities/opportunities to reap maximum profits out of their businesses and assist in decision making. Our team of in-house analysts and consultants works tirelessly to understand your needs and suggest the best possible solutions to fulfill your research requirements.

Our team at Reports Globe follows a rigorous process of data validation, which allows us to publish reports from publishers with minimum or no deviations. Reports Globe collects, segregates, and publishes more than 500 reports annually that cater to products and services across numerous domains.

Contact us:

Mr. Mark Willams

Account Manager

US: +1-970-672-0390

Email: [emailprotected]

Web: reportsglobe.com

Continue reading here:
Stem Cell Therapy Market Size, Top Key Players, Applications, Business Statistics, Trends and Forecast 2021-2027 The Bisouv Network - The Bisouv...

Stem Cells Market is Expected to Thrive at Impressive CAGR by 2025 Murphy’s Hockey Law – Murphy’s Hockey Law

This report studies the Stem Cells market size (value and volume) by players, regions, product types and end industries, history data 2013-2017 and forecast data 2018-2025; This report also studies the global market competition landscape, market drivers and trends, opportunities and challenges, risks and entry barriers, sales channels, distributors and Porters Five Forces Analysis.

Request Sample copy of this report athttps://www.precisionbusinessinsights.com/request-sample?product_id=30511

Stem cells are a class of undifferentiated cells that are able to differentiate into specialized cell types. Commonly, stem cells come from two main sources: Embryos formed during the blastocyst phase of embryological development (embryonic stem cells) and Adult tissue (adult stem cells).

Both types are generally characterized by their potency, or potential to differentiate into different cell types (such as skin, muscle, bone, etc.).

Stem Cells market, by technology, is Cell Acquisition, Cell Production, Cryopreservation, Expansion, and Sub-Culture. Stem Cell Therapy in China is not mature, so in this report we mainly cover Stem Cell Banking market.

Stem Cells market, by technology, is Cell Acquisition, Cell Production, Cryopreservation, Expansion, and Sub-Culture. Stem Cell Therapy in China is not mature, so in this report we mainly cover Stem Cell Banking market.

RequestCustomization copy of this report athttps://www.precisionbusinessinsights.com/request-customisation?product_id=30511

Geographically, this report is segmented into several key regions, with sales, revenue, market share and growth Rate of Stem Cells in these regions, from 2013 to 2025, covering

North America (United States, Canada and Mexico)

Europe (Germany, UK, France, Italy, Russia and Turkey etc.)

Asia-Pacific (China, Japan, Korea, India, Australia, Indonesia, Thailand, Philippines, Malaysia and Vietnam)

South America (Brazil etc.)

Middle East and Africa (Egypt and GCC Countries)

The various contributors involved in the value chain of the product include manufacturers, suppliers, distributors, intermediaries, and customers. The key manufacturers in this market include

CCBC

Vcanbio

Boyalife

Beikebiotech

By the product type, the market is primarily split into

Umbilical Cord Blood Stem Cell

Embryonic Stem Cell

Adult Stem Cell

Other

By the end users/application, this report covers the following segments

Diseases Therapy

Healthcare

We can also provide the customized separate regional or country-level reports, for the following regions:

North America

United States

Canada

Mexico

Asia-Pacific

China

India

Japan

South Korea

Australia

Indonesia

Singapore

Malaysia

Philippines

Thailand

Vietnam

Rest of Asia-Pacific

Europe

Germany

France

UK

Italy

Spain

Russia

Rest of Europe

Central & South America

Brazil

Rest of Central & South America

Middle East & Africa

GCC Countries

Turkey

Egypt

South Africa

Rest of Middle East & Africa

The study objectives of this report are:

To study and analyze the global Stem Cells market size (value & volume) by company, key regions/countries, products and application, history data from 2013 to 2017, and forecast to 2025.

To understand the structure of Stem Cells market by identifying its various subsegments.

To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).

Focuses on the key global Stem Cells manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.

To analyze the Stem Cells with respect to individual growth trends, future prospects, and their contribution to the total market.

To project the value and volume of Stem Cells submarkets, with respect to key regions (along with their respective key countries).

To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

To strategically profile the key players and comprehensively analyze their growth strategies.

About Us:

Precision Business Insights is one of the leading market research and management consulting firm, run by a group of seasoned and highly dynamic market research professionals with a strong zeal to offer high-quality insights. We at Precision Business Insights are passionate about market research and love to do the things in an innovative way. Our team is a big asset for us and great differentiating factor. Our company motto is to address client requirements in the best possible way and want to be a part of our client success. We have a large pool of industry experts and consultants served a wide array of clients across different verticals. Relentless quest and continuous endeavor enable us to make new strides in market research and business consulting arena.

Contact Us:

[emailprotected]

PH +1-866-598-1553

https://murphyshockeylaw.net/

See the rest here:
Stem Cells Market is Expected to Thrive at Impressive CAGR by 2025 Murphy's Hockey Law - Murphy's Hockey Law